Suppr超能文献

相似文献

2
Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy.
Gut. 2020 Jun;69(6):1116-1126. doi: 10.1136/gutjnl-2019-318841. Epub 2019 Sep 28.
7
Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.
Liver Int. 2011 May;31(5):700-6. doi: 10.1111/j.1478-3231.2011.02482.x. Epub 2011 Feb 20.
9
Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease.
Clin Gastroenterol Hepatol. 2005 Apr;3(4):384-9. doi: 10.1016/s1542-3565(04)00616-0.

引用本文的文献

2
Liver fibrosis progression analyzed with AI predicts renal decline.
JHEP Rep. 2025 Feb 12;7(5):101358. doi: 10.1016/j.jhepr.2025.101358. eCollection 2025 May.
5
Automated quantitative assay of fibrosis characteristics in tuberculosis granulomas.
Front Microbiol. 2024 Jan 3;14:1301141. doi: 10.3389/fmicb.2023.1301141. eCollection 2023.
6
Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions.
J Hepatol. 2024 Feb;80(2):335-351. doi: 10.1016/j.jhep.2023.10.015. Epub 2023 Oct 24.
7
Digital pathology for nonalcoholic steatohepatitis assessment.
Nat Rev Gastroenterol Hepatol. 2024 Jan;21(1):57-69. doi: 10.1038/s41575-023-00843-7. Epub 2023 Oct 3.
9
Second-Harmonic Generated Quantifiable Fibrosis Parameters Provide Signatures for Disease Progression and Regression in Nonalcoholic Fatty Liver Disease.
Clin Pathol. 2023 Mar 26;16:2632010X231162317. doi: 10.1177/2632010X231162317. eCollection 2023 Jan-Dec.

本文引用的文献

3
Data-driven desirability function to measure patients' disease progression in a longitudinal study.
J Appl Stat. 2016 Apr 1;43(5):783-795. doi: 10.1080/02664763.2015.1077378. Epub 2015 Oct 9.
4
Regulatory Science and Drug Approval for Alcoholic and Nonalcoholic Steatohepatitis.
Gastroenterology. 2016 Jun;150(8):1723-7. doi: 10.1053/j.gastro.2016.02.044. Epub 2016 Feb 26.
5
Nonalcoholic Fatty Liver Disease: Pros and Cons of Histologic Systems of Evaluation.
Int J Mol Sci. 2016 Jan 13;17(1):97. doi: 10.3390/ijms17010097.
6
End Points Must Be Clinically Meaningful for Drug Development in Nonalcoholic Fatty Liver Disease.
Gastroenterology. 2016 Jan;150(1):11-3. doi: 10.1053/j.gastro.2015.11.017. Epub 2015 Nov 18.
8
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.
Gastroenterology. 2015 Aug;149(2):389-97.e10. doi: 10.1053/j.gastro.2015.04.043. Epub 2015 Apr 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验